Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase II/III Trial Comparing Folririnox Association [Oxaliplatin / Irinotecan / LV5FU2] Versus Gemcitabine in First Line of Chemotherapy in Metastatics Pancreas Cancers Patients

NCT00112658 is registered in ClinicalTrials.gov with UNICANCER as lead sponsor.

NCT NCT00112658
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00112658 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase II/III Trial Comparing Folririnox Association [Oxaliplatin / Irinotecan / LV5FU2] Versus Gemcitabine in First Line of Chemotherapy in Metastatics Pancreas Cancers Patients
Lead sponsor
UNICANCER
Phase
Phase 2/3
Overall status
Completed
Start date
November 30, 2004
Completion date
June 30, 2010
Enrollment
342 (actual)
Sites
55

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer